Comprehensive viral screening panel: to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses as well as other rapidly emerging viruses that…
Ended Awarded Last action
- Contract number
- 75N93021F00001
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $513,550
Award facts
- Opportunity
-
- B07 Solicitation number
- Contract value 86% obligated
-
- $513,550.00 Current, with exercised options
- $595,173.16 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35233, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $30,100 | |
| Original award | $483,450 |
About this award
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to the University of Alabama at Birmingham (UAB) for a Comprehensive Viral Screening Panel to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses. The contract is a Delivery Order under the "In Vitro Assessments of Antimicrobial Activity (IVAAA)" Indefinite Delivery Contract (IDC), has a Firm Fixed Price of $595,173.16, and was awarded on August 16, 2021 with a completion date of August 15, 2022. The contract does not have a set-aside designation. UAB, a non-profit educational institution, will perform the work in Birmingham, Alabama. This award leverages UAB's expertise in biomedical research, healthcare, and infectious disease studies, which it has demonstrated through prior federal contracts and grants from agencies like NIH, CDC, DoD, and NSF.
Description
Comprehensive viral screening panel: to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses as well as other rapidly emerging viruses that utilize the same assay methodology.
Quick answers
Who was awarded contract 75N93021F00001?
75N93021F00001 was awarded to University Of Alabama At Birmingham by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 16, 2021.
How much is contract 75N93021F00001 worth?
The government has obligated $513,550 on 75N93021F00001. Its potential value, with all options, is $595,173.
Is contract 75N93021F00001 an order under another contract?
Yes. 75N93021F00001 is a delivery order under 75N93019D00016, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93021F00001 competed?
The extent of competition for 75N93021F00001 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award